FDA Investigator Barbara I Rogolsky
Barbara I Rogolsky has inspections in 3 countries as of 11 Nov 2022. Barbara I Rogolsky has collaborated with a combined 688 experts on various inspections, contributing to compliance and improvement across diverse sectors.
Investigator Details
Number of Inspected Sites:
3
Last Inspection Date:
11 Nov 2022
Investigator Role:
FDA Investigation Participant
Redica ID:
Country:
Japan,
United States of America,
India
Co-Investigator(s):
Angela E Glenn,
Barbara J Ragolsky,
Barbara L Rogolsky,
Brett R Havranek,
Bryce A Hammer,
Cheryl A Clausen,
Dana D Carter, SR DDS,
Devaugh Edwards,
Devaughn Edwards,
Helen Verdel,
Janete A Eaker,
Jogy George,
Johnson,
Joseph R Lambert,
Julianne C Mccullough,
Kellia N Hicks,
Kenneth H Williams,
Kenneth Nieves,
Lori A Gioia,
Luis A Dasta,
Martin J Kurek,
Matthew M Henciak,
Megan A Haggerty,
Melissa J Garcia,
Michael A Charles,
Michael A Feingold,
Nicole J Conklin,
Paige E Shelborne,
Paige E Wilson,
Robert J Martin,
Rozelle G Smith,
Saleem A Akhtar,
State Agency,
Stroman,
Tamara J Genetti,
Tamara J Umscheid,
Vani Mathur Richards,
Victoria A Wagoner,
Vlada Matusovsky,
Yumi J Hiramine
Barbara I Rogolsky's Documents
Publish Date | Document Type | Title |
---|---|---|
November, 2002 | FDA 483 | CIPLA LIMITED - Form 483, 2002-11-14 |
April, 2002 | EIR | Kyorin Pharmaceutical Group Facilities Co., Ltd. - EIR, 2002-04-11 |
November, 2002 | EIR | CIPLA LIMITED - EIR, 2003-01-17 |
April, 2004 | FDA 483 | Wilbur-Ellis Nutrition, LLC - Form 483, 2004-04-29 |
April, 2002 | FDA 483 | Kyorin Pharmaceutical Group Facilities Co., Ltd. - Form 483, 2002-04-11 |
April, 2004 | EIR | Wilbur-Ellis Nutrition, LLC - EIR, 2004-04-29 |
November, 2002 | FDA 483 Response | CIPLA LIMITED - Form 483R, 2002-12-02 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more